With a global team of more than 500 team members, Prenetics mission is to decentralize health care, and focuses on the comprehensive testing capabilities covering prevention, diagnostics, and personalized care.
This information enables people to make health a choice, by living healthier and proactively preventing and diagnosing diseases.
Danny Yeung is the Chief Executive Officer of Prenetics Group and sets business strategies and vision. Prior to Prenetics, Danny led multiple investments in DNA Genetic testing companies as Founding Partner/Investor at SXE Ventures. Previously, Danny founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to Danny leaving Groupon in early 2014, Danny served as CEO of Groupon East Asia, having scaled the business to a size of over USD $130m annually, overseeing a staff of 350 and being highly profitable. Danny’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong's award-winning dessert chain Hui Lau Shan into USA. After exiting Hui Lau Shan, Danny successfully ventured into hospitality furniture and executed multi-million dollar projects with MGM City Center, City of Dreams Macau and Venetian. Danny is currently a Founding Partner at SXE Ventures, Board Member at Parabase Genomics, Limited Partner and Mentor for 500 Startups. Danny received his BS in MIS from the University of San Francisco. Danny’s life motto is “Play Hard, Work Harder”.
Avi Lasarow is the Chief Executive Officer (Europe, Middle East and Africa) of Prenetics, responsible for international market growth outside of Asia Pacific and Americas. An award-winning lifestyle genetics pioneer on a mission to help people live happier and healthier lives, Avi has dedicated over a quarter of his life in the relentless pursuit of science and technological innovation. Avi’s career began at the consumer financial giant Citibank, before making a transition into founding a number of successful life sciences companies. The youngest ever Honorary Consul for South Africa to UK, Avi’s companies have also been highly decorated. In 2018 DNAFit received two Queens Awards for Enterprise, as well as a Board of Trade Award from the Department for International Trade. With Prenetics, he remains driven to advance and humanise a science that once seemed unreachable and inaccessible to so many.
Dr. Tzang is the Co-Founder and Chief Scientific Officer of Prenetics. Dr. Tzang is recognized as a leader in DNA based Molecular Diagnostic Techniques. Dr. Tzang has over 15 years industry experience and has spear-headed the development of over 30 proprietary panels, including DNA Microarray and Microfluidic platforms which has been used in research and in clinical settings. Dr. Tzang is also a Founding Member of the Hong Kong Society for Behavioural and Neural Genetics. Dr. Tzang holds seven global patents/patent applications and has authored 30 scientific articles. Dr. Tzang received his Ph.D in Genetics from City University of Hong Kong.
Stephen is the Chief Financial Officer of Prenetics, and oversees the accounting, finance, and operations functions. Before joining Prenetics, Stephen was a Vice President in the Asia Pacific Investment Banking team of Citigroup, where he completed initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the US. Prior to investment banking, Stephen was a senior auditor with Ernst & Young. Stephen graduated from Yale University’s School of Management, the London School of Economics and Political Science and Hong Kong Baptist University. He is a Certified Public Accountant and has completed the CFA Program.
Dr. Wong, DPhil (Oxon), is the Chief Technology Officer of Prenetics and is responsible for driving technology vision and roadmap, and engineering delivery. Prior to Prenetics, Peter was the Head of Engineering at Travelex, where he led its first digital transformation and successfully delivered a brand new international money transfer service, Travelex Wire. Peter also led Travelex's B2B business, and launched its first international payment platform with the World Bank Group. Peter has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events such as AWS Summit and at universities. Peter holds a Doctorate degree in Computer Science from the University of Oxford, and BSc and MSc degrees in Computer Science from the University of Warwick.
Dr. Sundaram, MD, is the Chief Clinical Officer of Prenetics. Dr. Sundaram is highly recognised for his experience as a physician-scientist，having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works have been funded by the National Institute of Health (NIH), USA. Dr. Sundaram also serves as a reviewer of different journals and NIH study sections.
Dr. Cheung serves as Vice President (Research & Development) and has been instrumental in the creation of the company’s proprietary assay platform. Dr. Cheung has over 13 years In-Vitro Diagnostic (IVD) industry experience in product development as well as clinical settings. Dr. Cheung managed over 18 M HKD grants, and was previously the Principal Researcher in a joint collaboration study between Hong Kong Government and a consortium of listed companies in the bio-tech space. Dr. Cheung holds 7 global patents /patent applications and has published 16 scientific articles. Dr. Cheung received her Ph.D in Biochemistry from The Hong Kong Polytechnic University.
Dr. Ma serves as Vice President of Clinical Operations in Prenetics and is responsible for Clinical R&D and Product Implementation. Dr. Ma has over 25 years of industry experience in molecular diagnostic, point-of-care POC technologies, product validation and clinical trial. Before joining Prenetics in 2019, he held senior R&D and clinical application positions at molecular diagnostic companies in China and the U.S., including Exact Sciences, Hologic and Third Wave Technologies. Dr. Ma holds 14 global patents/patent applications and has published 11 scientific articles. Dr. Ma received his Ph.D. in Medicinal Chemistry & Molecular Pharmacology from Purdue University.
Clinical Development (Certified Principal Investigator, Certified Clinical Research Professional, Medical Monitor) and Medical Affairs physician in industry with clinical fellowship specialization in medical genetics and sub-specialization in clinical molecular genomics laboratory testing for hereditary oncology, common and rare hereditary adult and pediatric conditions, pharmacogenetics, carrier screening, and women's health. Leadership experiences in start-up to mega-cap with in vitro diagnostics (IVD) test development, clinical verification and validation, registrational studies and submissions.